104 related articles for article (PubMed ID: 16278853)
21. Mitochondrial Dysfunction in Alzheimer's Disease: Opportunities for Drug Development.
Bhatia S; Rawal R; Sharma P; Singh T; Singh M; Singh V
Curr Neuropharmacol; 2022; 20(4):675-692. PubMed ID: 33998995
[TBL] [Abstract][Full Text] [Related]
22. Amyloid PET Imaging in Self-Identified Non-Hispanic Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study.
Deters KD; Napolioni V; Sperling RA; Greicius MD; Mayeux R; Hohman T; Mormino EC
Neurology; 2021 Mar; 96(11):e1491-e1500. PubMed ID: 33568538
[TBL] [Abstract][Full Text] [Related]
23. Genetic variants for personalised management of very low carbohydrate ketogenic diets.
Aronica L; Volek J; Poff A; D'agostino DP
BMJ Nutr Prev Health; 2020 Dec; 3(2):363-373. PubMed ID: 33521546
[TBL] [Abstract][Full Text] [Related]
24. Genetic architecture of Alzheimer's disease.
Neuner SM; Tcw J; Goate AM
Neurobiol Dis; 2020 Sep; 143():104976. PubMed ID: 32565066
[TBL] [Abstract][Full Text] [Related]
25. APOE region molecular signatures of Alzheimer's disease across races/ethnicities.
Kulminski AM; Shu L; Loika Y; Nazarian A; Arbeev K; Ukraintseva S; Yashin A; Culminskaya I
Neurobiol Aging; 2020 Mar; 87():141.e1-141.e8. PubMed ID: 31813627
[TBL] [Abstract][Full Text] [Related]
26. Association between Apolipoprotein E Gene Polymorphism and Alzheimer's Disease in an Iranian Population: A Meta-Analysis.
Abyadeh M; Djafarian K; Heydarinejad F; Alizadeh S; Shab-Bidar S
J Mol Neurosci; 2019 Dec; 69(4):557-562. PubMed ID: 31444704
[TBL] [Abstract][Full Text] [Related]
27.
Choi KY; Lee JJ; Gunasekaran TI; Kang S; Lee W; Jeong J; Lim HJ; Zhang X; Zhu C; Won SY; Choi YY; Seo EH; Lee SC; Gim J; Chung JY; Chong A; Byun MS; Seo S; Ko PW; Han JW; McLean C; Farrell J; Lunetta KL; Miyashita A; Hara N; Won S; Choi SM; Ha JM; Jeong JH; Kuwano R; Song MK; An SSA; Lee YM; Park KW; Lee HW; Choi SH; Rhee S; Song WK; Lee JS; Mayeux R; Haines JL; Pericak-Vance MA; Choo ILH; Nho K; Kim KW; Lee DY; Kim S; Kim BC; Kim H; Jun GR; Schellenberg GD; Ikeuchi T; Farrer LA; Lee KH; Neuroimaging Initative AD
J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31426376
[TBL] [Abstract][Full Text] [Related]
28. Impact of Apolipoprotein E gene polymorphism during normal and pathological conditions of the brain across the lifespan.
Iacono D; Feltis GC
Aging (Albany NY); 2019 Jan; 11(2):787-816. PubMed ID: 30677746
[TBL] [Abstract][Full Text] [Related]
29. Targeted Sequencing of Alzheimer Disease Genes in African Americans Implicates Novel Risk Variants.
Logue MW; Lancour D; Farrell J; Simkina I; Fallin MD; Lunetta KL; Farrer LA
Front Neurosci; 2018; 12():592. PubMed ID: 30210277
[TBL] [Abstract][Full Text] [Related]
30. 'Evolutionary medicine' perspectives on Alzheimer's Disease: Review and new directions.
Fox M
Ageing Res Rev; 2018 Nov; 47():140-148. PubMed ID: 30059789
[TBL] [Abstract][Full Text] [Related]
31. APOE and Alzheimer's Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer's Pathogenesis.
Uddin MS; Kabir MT; Al Mamun A; Abdel-Daim MM; Barreto GE; Ashraf GM
Mol Neurobiol; 2019 Apr; 56(4):2450-2465. PubMed ID: 30032423
[TBL] [Abstract][Full Text] [Related]
32. APOE ε4-TOMM40 '523 haplotypes and the risk of Alzheimer's disease in older Caucasian and African Americans.
Yu L; Lutz MW; Wilson RS; Burns DK; Roses AD; Saunders AM; Yang J; Gaiteri C; De Jager PL; Barnes LL; Bennett DA
PLoS One; 2017; 12(7):e0180356. PubMed ID: 28672022
[TBL] [Abstract][Full Text] [Related]
33. Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.
Yamazaki Y; Painter MM; Bu G; Kanekiyo T
CNS Drugs; 2016 Sep; 30(9):773-89. PubMed ID: 27328687
[TBL] [Abstract][Full Text] [Related]
34. Inverse effect of the APOE epsilon4 allele in late- and early-onset Alzheimer's disease.
De Luca V; Orfei MD; Gaudenzi S; Caltagirone C; Spalletta G
Eur Arch Psychiatry Clin Neurosci; 2016 Oct; 266(7):599-606. PubMed ID: 26714935
[TBL] [Abstract][Full Text] [Related]
35. Nervous system disorders across the life course in resource-limited settings.
Birbeck GL; Meyer AC; Ogunniyi A
Nature; 2015 Nov; 527(7578):S167-71. PubMed ID: 26580323
[TBL] [Abstract][Full Text] [Related]
36. Global and local ancestry in African-Americans: Implications for Alzheimer's disease risk.
Hohman TJ; Cooke-Bailey JN; Reitz C; Jun G; Naj A; Beecham GW; Liu Z; Carney RM; Vance JM; Cuccaro ML; Rajbhandary R; Vardarajan BN; Wang LS; Valladares O; Lin CF; Larson EB; Graff-Radford NR; Evans D; De Jager PL; Crane PK; Buxbaum JD; Murrell JR; Raj T; Ertekin-Taner N; Logue MW; Baldwin CT; Green RC; Barnes LL; Cantwell LB; Fallin MD; Go RC; Griffith P; Obisesan TO; Manly JJ; Lunetta KL; Kamboh MI; Lopez OL; Bennett DA; Hardy J; Hendrie HC; Hall KS; Goate AM; Lang R; Byrd GS; Kukull WA; Foroud TM; Farrer LA; Martin ER; Pericak-Vance MA; Schellenberg GD; Mayeux R; Haines JL; Thornton-Wells TA;
Alzheimers Dement; 2016 Mar; 12(3):233-43. PubMed ID: 26092349
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology of Dementia among the Elderly in Sub-Saharan Africa.
Olayinka OO; Mbuyi NN
Int J Alzheimers Dis; 2014; 2014():195750. PubMed ID: 25177512
[TBL] [Abstract][Full Text] [Related]
38. Epidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review.
Lekoubou A; Echouffo-Tcheugui JB; Kengne AP
BMC Public Health; 2014 Jun; 14():653. PubMed ID: 24969686
[TBL] [Abstract][Full Text] [Related]
39. Exercise, APOE genotype, and the evolution of the human lifespan.
Raichlen DA; Alexander GE
Trends Neurosci; 2014 May; 37(5):247-55. PubMed ID: 24690272
[TBL] [Abstract][Full Text] [Related]
40. APOE ε4 and the risk for Alzheimer disease and cognitive decline in African Americans and Yoruba.
Hendrie HC; Murrell J; Baiyewu O; Lane KA; Purnell C; Ogunniyi A; Unverzagt FW; Hall K; Callahan CM; Saykin AJ; Gureje O; Hake A; Foroud T; Gao S
Int Psychogeriatr; 2014 Jun; 26(6):977-85. PubMed ID: 24565289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
